Development of radiosensitivity biomarkers in women candidate to early mammography screening, and investigation of underlying molecular determinants.
Evaluating the anti-tumor potential of PARP inhibitor treatment in combination with dendritic cell-based therapies in triple negative breast cancer
Deciphering the dendritic cell compartment in ovarian cancer to assess their potential as tumor vaccines.
Deciphering the dendritic cell compartment in ovarian cancer to assess their potential as tumor vaccines.
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2
Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families.
The clinical characteristics of breast cancers with a familial risk in which no BRCA1/2 mutations were found are sometimes suggestive for a genetic etiology
Association of PHB 1630 C > T and MTHFR 677 C > T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study
Prevalence of BRCA1 and BRCA2 Mutations in Patients with Primary Ovarian Cancer - Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?